Bronchopulmonary Dysplasia and Chronic Lung Disease: Stem Cell Therapy

Clinics in Perinatology

Volumn 42, Issue 4, 2015, Pages 889-910

  Pierro, Maria ^a,b   Ciarmoli, Elena ^c   Thébaud, Bernard ^d,e,f  

^a UNIVERSITY OF MILAN   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bronchopulmonary dysplasia; Clinical translation; Newborn; Prematurity; Stem cells

Indexed keywords

SURFACTANT;

CELL PROLIFERATION; CHRONIC LUNG DISEASE; DEVELOPMENTAL STAGE; GENE EXPRESSION; HUMAN; HYPEROXIA INDUCED LUNG INJURY; INFLAMMATION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FIBROSIS; LUNG INJURY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; ORGANOGENESIS; OXIDATIVE STRESS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RAT; REVIEW; STEM CELL TRANSPLANTATION; TRANSCRIPTION REGULATION; ANIMAL; BRONCHOPULMONARY DYSPLASIA; CHRONIC DISEASE; EMBRYOLOGY; GROWTH, DEVELOPMENT AND AGING; LUNG; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; NEWBORN; PREMATURITY; PROCEDURES;

ANIMALS; ANIMALS, NEWBORN; BRONCHOPULMONARY DYSPLASIA; CHRONIC DISEASE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; STEM CELL TRANSPLANTATION;

EID: 84947588016     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2015.08.013     Document Type: Review

References (75)

1. Jobe A.H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 163:1723-1729.
2. Farstad T., Bratlid D., Medbo S., et al. Bronchopulmonary dysplasia - prevalence, severity and predictive factors in a national cohort of extremely premature infants. Acta Paediatr 2011, 100:53-58.
3. Prockop D.J., Kota D.J., Bazhanov N., et al. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med 2010, 14:2190-2199.
4. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
5. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006, 119:2204-2213.
6. Collins J.J., Thébaud B. Progenitor cells of the distal lung and their potential role in neonatal lung disease. Birth Defects Res A Clin Mol Teratol 2014, 100(3):217-226.
7. Popova A.P., Bozyk P.D., Goldsmith A.M., et al. Autocrine production of TGF-beta1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol 2010, 298:L735-L743.
8. Popova A.P., Bozyk P.D., Bentley J.K., et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010, 126:e1127-e1133.
9. van Haaften T., Byrne R., Bonnet S., et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009, 180:1131-1142.
10. Coalson J.J. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003, 8:73-81.
11. Berger J., Bhandari V. Animal models of bronchopulmonary dysplasia. The term mouse models. Am J Physiol Lung Cell Mol Physiol 2014, 307:L936-L947.
12. O'Reilly M., Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol 2014, 307:L948-L958.
13. Aslam M., Baveja R., Liang O.D. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009, 180:1122-1130.
14. Chang Y.S., Oh W., Choi S.J. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2009, 18:869-886.
15. Chang Y.S., Choi S.J., Sung D.K. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011, 20:1843-1854.
16. Chang Y.S., Choi S.J., Ahn S.Y. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One 2013, 8:e52419.
17. Pierro M., Ionescu L., Montemurro T., et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013, 68:475-484.
18. Rossor T., Greenough A. Advances in paediatric pulmonary vascular disease associated with bronchopulmonary dysplasia. Expert Rev Respir Med 2014, 26:1-9.
19. Nagiub M., Lee S., Guglani L. Echocardiographic assessment of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review of literature and a proposed algorithm for assessment. Echocardiography 2014, 32(5):819-833.
20. Thebaud B., Abman S.H. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007, 175:978-985.
21. Speer C.P. Role of inflammation in the evolution of bronchopulmonary dysplasia. J Perinatol 2006, (Suppl 1):S57-S62.
22. Thompson A., Bhandari V. Pulmonary biomarkers of bronchopulmonary dysplasia. Biomark Insights 2008, 3:361-373.
23. Jankov R.P., Negus A., Tanswell A.K. Antioxidants as therapy in the newborn: some words of caution. Pediatr Res 2001, 50:681-687.
24. Saugstad O.D. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 2003, 8:39-49.
25. O'Reilly M., Thébaud B. Using cell-based strategies to break the link between bronchopulmonary dysplasia and the development of chronic lung disease in later life. Pulm Med 2013, 2013:874161.
26. Vom Hove M., Prenzel F., Uhlig H.H., et al. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 2014, 164:40-45.e4.
27. Fawke J., Lum S., Kirkby J., et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010, 182:237-245.
28. Wong P.M., Lees A.N., Louw J., et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J 2008, 32:321-328.
29. Ren G., Chen X., Dong F., et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 2012, 1:51-58.
30. Ma S., Xie N., Li W., et al. Immunobiology of mesenchymal stem cells. Cell Death Differ 2014, 21:216-225.
31. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
32. Krause D.S., Theise N.D., Collector M.I., et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001, 105:369-377.
33. Sueblinvong V., Loi R., Eisenhauer P.L., et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008, 177:701-711.
34. Murphy M.B., Moncivais K., Caplan A.I. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013, 45:e54.
35. Fung M.E., Thébaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014, 75:2-7.
36. Tropea K.A., Leder E., Aslam M., et al. Bronchoalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012, 302:L829-L837.
37. Lee J.W., Fang X., Krasnodembskaya A., et al. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011, 29:913-919.
38. Chaput N., Thery C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011, 33:419-440.
39. Lee C., Mitsialis S.A., Aslam M., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126:2601-2611.
40. Islam M.N., Das S.R., Emin M.T., et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18:759-765.
41. Dong J., Carey W.A., Abel S., et al. MicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia. BMC Genomics 2012, 13:204.
42. Waszak P., Alphonse R., Vadivel A., et al. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012, 21:2789-2797.
43. Le Blanc K., Tammik C., Rosendahl K., et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
44. Gebler A., Zabel O., Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012, 18:128-134.
45. Le Blanc C., Davies L.C. Mesenchymal stromal cells and the innate immune response. Immunol Lett 2015, [Epub ahead of print].
46. Deuse T., Stubbendorff M., Tang-Quan K., et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 2011, 20:655-667.
47. Najar M., Raicevic G., Boufker H.I., et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010, 264:171-179.
48. Batsali K.A., Kastrinaki M.C., Papadaki H., et al. Mesenchymal stem cells derived from Wharton's jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther 2013, 8:144-155.
49. Huang X.-P., Sun Z., Miyagi Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010, 122:2419-2429.
50. Crop M.J., Korevaar S.S., de Kuiper R., et al. Human mesenchymal stem cells are susceptible to lysis by CD8fl T-cells and NK cells. Cell Transplant 2011, 20:1547-1559.
51. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. J Am Med Assoc 2012, 308:2369-2379.
52. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
53. Kuzmina L.A., Petinati N.A., Parovichnikova E.N., et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int 2012, 2012:968213.
54. Yan X., Liu Y., Han Q., et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1(1) mesenchymal stem cell in lung. Exp Hematol 2007, 35:1466-1475.
55. Stoll B.J., Hansen N.I., Bell E.F., et al. Neonatal outcomes of extremely preterm infants from the NICHD neonatal research network. Pediatrics 2010, 126:443-456.
56. Walsh M.C., Szefler S., Davis J., et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 2006, 117:S52-S55.
57. Patel R.M., Kandefer S., Walsh M.C., et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med 2015, 372:331-340.
58. Lee R.H., Pulin A.A., Seo M.J., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
59. Schrepfer S., Deuse T., Reichenspurner H., et al. Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39:573-576.
60. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
61. Chang Y.S., Ahn S.Y., Yoo H.S., et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014, 164:966-972.
62. Mueller S.M., Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001, 82:583-590.
63. Castro-Malaspina H., Gay R.E., Resnick G., et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980, 56:289-301.
64. Dmitrieva R.I., Minullina I.R., Bilibina A.A., et al. Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities. Cell Cycle 2012, 11:377-383.
65. Li X., Bai J., Ji X., et al. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med 2014, 34(3):695-704.
66. Jin H.J., Bae Y.K., Kim M., et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013, 14:17986-18001.
67. Hsieh J.Y., Fu Y.S., Chang S.J., et al. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord. Stem Cells Dev 2010, 19:1895-1910.
68. Hsieh J.Y., Wang H.W., Chang S.J., et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 2013, 8:e72604.
69. Rombouts W.J.C., Ploemacher R.E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003, 17:160-170.
70. Sethe S., Scutt A., Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006, 5:91-116.
71. Kern S., Eichler H., Stoeve J., et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
72. Thirumala S., Goebel W.S., Woods E.J. Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther 2013, 13:673-691.
73. Alagesan S., Griffin M.D. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?. Curr Opin Organ Transplant 2014, 19:65-72.
74. Lalu M.M., McIntyre L., Pugliese C., Canadian Critical Care Trials Group, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012, 7:e47559.
75. Zheng G.P., Ge M.H., Shu Q., et al. Mesenchymal stem cells in the treatment of pediatric diseases. World J Pediatr 2013, 9:197-211.